Sfoglia per AUTORE
FIEDLER WM
Collezione AO Cuneo

  

Items : 1

First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study in Journal of Clinical Oncology

2019
AO Cuneo

Loges S; Heuser M; Chromik J; Vigil CE; Paschka P; Re F; Di Renzo N; Lemoli R; Mattei D; Batalla IB; Hellesøy M; Micklem D; Holt RJ; Lorens K; Lorens JB; Shoaib M; Aly H; Fiedler WM; Cortes JE; Gjertsen BT;